Metotab

Methotrexate, the active ingredient in Metotab, is an antimetabolite presented as an oral tablet for oral use. It treats rheumatoid arthritis, psoriasis, certain cancers and Crohn's disease in adult patients.\n\nGNH India supplies Metotab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is employed in autoimmune and oncologic conditions that involve rapid cell proliferation.\n\nRheumatoid arthritis: reduces joint inflammation and slows disease progression.\nPsoriasis: decreases severity of skin lesions.\nCertain cancers (e.g., leukemia, lymphoma): interferes with tumor cell growth.\nCrohn's disease: helps achieve remission in moderate‑to‑severe disease.

Methotrexate may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea or vomiting\n- Mouth sores (stomatitis)\n- Fatigue\n- Mild elevation of liver enzymes\n\nSerious or Rare Side Effects:\n- Bone marrow suppression leading to low blood counts\n- Severe liver toxicity (hepatitis, fibrosis)\n- Pulmonary toxicity (interstitial pneumonitis)\n- Life‑threatening skin reactions such as Stevens‑Johnson syndrome

Methotrexate requires careful monitoring and specific safety measures.\n\nPregnancy: contraindicated (Category X) – avoid use in pregnant women.\nMonitoring: regular blood counts and liver function tests are essential.\nRenal function: assess before initiation and adjust if impaired.\nConcomitant NSAIDs: avoid high‑dose NSAIDs to reduce toxicity risk.\nAlcohol: limit intake to minimize liver damage.\nStore at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Methotrexate interacts with several medicines that can alter its safety or effectiveness.\n\nMajor Interactions (Avoid):\n- Live attenuated vaccines: increased risk of infection.\n- Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression.\n- High‑dose NSAIDs: heightened methotrexate toxicity.\n\nModerate Interactions (Monitor Closely):\n- Oral contraceptives: may reduce contraceptive efficacy.\n- ACE inhibitors or ARBs: can affect renal clearance of methotrexate.\n- Allopurinol: may increase methotrexate plasma levels.